TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16188207
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (60 g)
Study: 12816171
Drug: High-dose lisinopril
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose lisinopril (32.5-35.0 mg/day)
Study: 31421664
Drug: Shallot (3g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shallot (3g per day) and cetirizine (10 mg once daily)
Study: 31421664
Drug: Cetirizine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine (10 mg once daily) and placebo capsules
Study: 29183775
Drug: Isoflavone pills
Normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavone pills (60 mg genistein, 60 mg daidzein, 16.6 mg glycitein)
Study: 14575666
Drug: Bilateral injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral injection of hypertonic saline (two injections)
Study: 14575666
Drug: Unilateral injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unilateral injection of hypertonic saline (one injection)
Study: 26809813
Drug: Gatifloxacin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gatifloxacin (10 mg/kg per day for 7 days)
Study: 26809813
Drug: Ceftriaxone (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (60 mg/kg up to 2 g per day for 7 days)
Study: 8774269
Drug: Creatine supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplement (5 g of creatine plus 1 g of glucose)
Study: 8774269
Drug: Glucose placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose placebo (6 g of glucose)
Study: 1377412
Drug: DDAVP infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: DDAVP infusion
Study: 27304196
Drug: Vorapaxar (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vorapaxar (2.5 mg q.d. for 7 days)
Study: 27304196
Drug: Aspirin (81
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (81 mg q.d. for 7 days)
Study: 27304196
Drug: Vorapaxar +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vorapaxar + Aspirin (for 7 days)
Study: 27304196
Drug: Aspirin (for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (for 7 days)
Study: 24699310
Drug: Sativex(®) low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sativex(®) low dose (5.4mg THC)
Study: 24699310
Drug: Sativex(®) high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sativex(®) high dose (21.6mg THC)
Study: 23896849
Drug: Cognitive remediation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive remediation with supplemental Internet-based homework (10 weeks of weekly group sessions and daily online cognitive exercises)
Study: 20843504
Drug: Diclectin (doxylamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclectin (doxylamine succinate 10 mg-pyridoxine hydrochloride 10 mg, delayed-release preparation)
Study: 8737752
Drug: Spirapril 3
Normalized name: spirapril 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spirapril 3 mg and 6 mg
Study: 1331494
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate (0.3 g kg‐1 body mass)
Study: 23680589
Drug: Intravenous (i.v.)
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (i.v.) iron (Iron Sucrose 200 mg, once a week for 5 weeks)
Study: 23680589
Drug: Oral (p.o.)
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral (p.o.) iron (ferrous sulfate 200 mg TID for 8 weeks)
Study: 21642644
Drug: Phenylephrine (100-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine (100-200 µg)
Study: 21642644
Drug: Ephedrine (5-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine (5-20 mg)
Study: 16719616
Drug: Applied tension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Applied tension technique (treatment condition)
Study: 9209247
Drug: Oral cotinine
Normalized name: Chinine
DrugBank: Quinine (DB00468)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral cotinine treatment (0.25 mg/kg twice a day)
Study: 9209247
Drug: Low-dose cotinine-d4
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cotinine-d4 infusion
Study: 8080160
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid solution containing acetate
Study: 8080160
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid solution without acetate
Study: 29321067
Drug: Mechanical Oral
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical Oral Hygiene (MOH) only
Study: 24188861
Drug: Helping Alliance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Helping Alliance Questionnaire I (measured twice, middle and late during treatment)
Study: 20530276
Drug: ixabepilone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: ixabepilone (40 mg/m² intravenously on day 1) plus capecitabine (2,000 mg/m² orally on days 1 through 14)
Study: 20530276
Drug: capecitabine alone
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: capecitabine alone (2,500 mg/m² on the same schedule)
Study: 16633890
Drug: Budesonide (Dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (Dosage Form A, 3 mg)
Study: 16633890
Drug: Budesonide (Dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (Dosage Form A, 9 mg)
Study: 16633890
Drug: Budesonide (Dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (Dosage Form B, 9 mg)
Study: 10663279
Drug: Ranitidine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine alone (150 mg preoperatively per os and 50 mg intravenously postoperatively)
Study: 10663279
Drug: Ranitidine combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine combined with dobutamine (150 mg preoperatively per os and 50 mg intravenously postoperatively + dobutamine 4 micro g. kg(‐1). min(‐1) for 3 h postoperatively)
Study: 10663279
Drug: Dobutamine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dobutamine alone (4 micro g. kg(‐1). min(‐1) for 3 h postoperatively)
Study: 8797464
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (1 g/kg body weight/day for 2 days, total dose 2.0 g/kg body weight)
Study: 15209626
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (IFN-alpha-2b + hepatitis B vaccine)
Study: 15209626
Drug: IFN-alpha-2b monotherapy
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IFN-alpha-2b monotherapy
Study: 11324727
Drug: Twice-daily 3
Normalized name: diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Twice-daily 3 MU of IFN beta (group A)
Study: 11324727
Drug: Once-daily 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily 6 MU of IFN-beta (group B)
Study: 3285170
Drug: Lidocaine 1
Normalized name: lidocaine 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 1 mg. kg‐1
Study: 30690691
Drug: VEL-091604 cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: VEL-091604 cream applied 2 times daily for 2 weeks
Study: 30690691
Drug: VEL-091604 cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: VEL-091604 cream in atopic dermatitis subjects
Study: 26462570
Drug: Short-term meditation
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term meditation (MG) with positive suggestions
Study: 26462570
Drug: Short-term meditation
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term meditation (MG) with negative suggestions
Study: 22592214
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution (0.9% NaCl)
Study: 19878508
Drug: Etanercept 50
Normalized name: etanercept 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 50 mg weekly for 4 weeks
Study: 11828040
Drug: Logistic regression
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Logistic regression model with symptoms, free running test, and methacholine inhalation challenge results
Study: 10036612
Drug: Haloperidol 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 1.0 mg
Study: 10036612
Drug: Haloperidol 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 2.0 mg
Study: 6944708
Drug: Reserpine 0.5
Normalized name: reserpine 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reserpine 0.5 mg i.m.
Study: 6944708
Drug: Haloperidol 0.5
Normalized name: haloperidol 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 0.5 mg i.m.
Study: 31713262
Drug: Extended sensory
Normalized name: aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Extended sensory intervention (SI) with additional weekly visits from a sensory support therapist (SST)
Study: 22571890
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (statistical treatment guidelines for AAA)
Study: 12418673
Drug: Liquid DTP/PRP-T
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid DTP/PRP-T formulation
Study: 12418673
Drug: Liquid DTP/PRP-T
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid DTP/PRP-T formulation (Part 2)
Study: 12418673
Drug: Booster dose
Normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster dose of PRP-T/DTP
Study: 31855498
Drug: Antioxidant supplements
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant supplements (vitamins A, C, and E; carotenoids; coenzyme Q10) before and during treatment
Study: 31855498
Drug: Vitamin B12
Normalized name: Vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin B12 use before and during chemotherapy
Study: 31855498
Drug: Iron use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron use during chemotherapy
Study: 28416405
Drug: SLEEP Inventory
Approvals — FDA: no, EMA: no, PMDA: no
Description: SLEEP Inventory (Sex, Left heart failure, ESS, Enlarged neck, weight [in Pounds], Insulin resistance/diabetes, and National Institutes of Health Stroke Scale)
Study: 23381494
Drug: Intranasal mometasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal mometasone furoate (MF) for 6 weeks
Study: 10861916
Drug: Risperidone (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (mean dose 3.7 mg/day)
Study: 10861916
Drug: Conventional antipsychotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional antipsychotic agents (historical control)
Study: 2874825
Drug: Ketanserin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (20 or 40 mg)
Study: 28436580
Drug: Rescue antenatal
Normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rescue antenatal steroids (AS)
Study: 24495273
Drug: Donepezil hydrochloride
Normalized name: Donepezil Hydrochloride
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Donepezil hydrochloride orally disintegrating tablet (ODT) with 10 mg of ammonium glycyrrhizinate
Study: 17563023
Drug: Sequential counseling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential counseling (addressing a new behavior every 6 months)
Study: 17563023
Drug: Sequential counseling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential counseling
Study: 12719667
Drug: Topical ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical ciprofloxacin (group A)
Study: 12719667
Drug: Topical norfloxacin
Normalized name: Norfloxacin
DrugBank: Norfloxacin (DB01059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical norfloxacin (group B)
Study: 11035829
Drug: LCPUFA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCPUFA supplementation (fat supplement supplying 26% as fatty acids including DHA, 8%)
Study: 1406879
Drug: Deferoxamine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferoxamine (100 mg/kg/day for 72 hours)
Study: 3899674
Drug: RU 28318
Normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RU 28318 100 mg (9 alpha‐FHC ingestion)
Study: 3899674
Drug: RU 28318
Normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RU 28318 200 mg (aldosterone infusion)
Study: 3899674
Drug: RU 28318
Normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RU 28318 100 mg (furosemide ingestion)
Study: 3899674
Drug: RU 28318
Normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RU 28318 300 mg (furosemide ingestion)
Study: 3899674
Drug: Spironolactone (identical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (identical doses to RU 28318)
Study: 12839693
Drug: rhIL-11 (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhIL-11 (25 microg/kg body weight, subcutaneously once daily for 7 to 14 days)
Study: 30663077
Drug: Pregabalin 225
Normalized name: pregabalin 225 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 225 mg twice daily for 12 weeks
Study: 28935772
Drug: Carfilzomib in
Normalized name: carfilzomib Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carfilzomib in combination with lenalidomide and dexamethasone (CRd)
Study: 29915914
Drug: Regular aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular aspirin use
Study: 22182951
Drug: Cranial OMM
Normalized name: geranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranial OMM augmentation technique
Study: 22182951
Drug: Cranial OMM
Normalized name: geranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranial OMM and sham therapy
Study: 11305826
Drug: Group I
Normalized name: Platelet group IIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group I - 20 mg lidocaine plus 25 microg fentanyl
Study: 11305826
Drug: Group II
Normalized name: Platelet group IIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group II - 20 mg lidocaine plus 10 microg sufentanil
Study: 11305826
Drug: Group III
Normalized name: Corticosteroids, potent (group III)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group III - 10 mg lidocaine plus 10 microg sufentanil
Study: 31906766
Drug: Gait training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gait training with the Biodex Gait Trainer 3 (a treadmill integrated with music therapy)
Study: 29563779
Drug: Enteral nutrition
Normalized name: ENTERAL NUTRITION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral nutrition (500 mL·d‐1 for 1 month)
Study: 29563779
Drug: Enteral nutrition
Normalized name: ENTERAL NUTRITION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral nutrition (500 mL·d‐1 for 3 months)
Study: 25528251
Drug: no local
Approvals — FDA: no, EMA: no, PMDA: no
Description: no local hemostatic agents
Study: 18849063
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg intramuscular (IM) dimenhydrinate
Study: 18849063
Drug: 2 mL
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mL IM saline solution (placebo)
Study: 11230840
Drug: Omapatrilat (high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omapatrilat (high-dose groups)
Study: 8565032
Drug: Nifedipine coat-core
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine coat-core 30 mg
Study: 8565032
Drug: Nifedipine coat-core
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine coat-core 60 mg
Study: 2350875
Drug: Indomethacin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (50 mg intravenously)
Study: 24277399
Drug: Early oral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early oral feeding group
Study: 18499623
Drug: PERI group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: PERI group receiving intraoperative and postoperative ketamine (2 microg x kg(‐1) x min(‐1) after a 0.5 mg/kg bolus)
Study: 18499623
Drug: INTRA group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: INTRA group receiving intraoperative ketamine (2 microg x kg(‐1) x min(‐1) after a 0.5 mg/kg bolus)
Study: 16542203
Drug: Lamotrigine 200
Normalized name: lamotrigine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamotrigine 200 mg day(-1) and Olanzapine 15 mg day(-1) coadministration (LTG + OLZ group)
Study: 16542203
Drug: Lamotrigine 200
Normalized name: lamotrigine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamotrigine 200 mg day(-1) with placebo (LTG group)
Study: 16542203
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with Olanzapine 15 mg day(-1) (OLZ group)
Study: 12716329
Drug: Guided Tissue
Normalized name: tissue respiratory factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided Tissue Regeneration (GTR) - ePTFE membranes (Gore‐Tex W.L. Gore and Associates, Flagstaff, AZ, USA)
Study: 11113227
Drug: Cladribine (0.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cladribine (0.7 mg/kg and 2.1 mg/kg)
Study: 9762661
Drug: Virus-specific oligoclonal
Normalized name: rubella virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virus-specific oligoclonal IgG antibodies
Study: 2841177
Drug: Oral Glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Glucose Load
Study: 30511958
Drug: Twister wrap
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twister wrap orthosis (TWO) in addition to conventional physical therapy and ankle foot orthosis (AFO)
Study: 30511958
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical therapy and ankle foot orthosis (AFO)
Study: 25331468
Drug: Allitridi capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allitridi capsules (120 mg/day)
Study: 21174182
Drug: Multimodal analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal analgesic approach (MMA) including paravertebral blocks with 0.5% ropivacaine, celecoxib (400 mg po prior to surgery and 200 mg po bid for seven days), and ketamine (10 mg iv)
Study: 21174182
Drug: Multimodal analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal analgesic approach (MMA)
Study: 7817261
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for exophytic warts or clinical symptoms (n = 55)
Study: 3061032
Drug: Indoramin (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indoramin (initial dose 50 mg/d)
Study: 3061032
Drug: Propranolol (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (initial dose 80 mg/d)
Study: 24321138
Drug: Diesel exhaust
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diesel exhaust exposure (PM1300 μg/m(3))
Study: 24321138
Drug: Filtered air
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filtered air exposure (PM12 μg/m(3))
Study: 16647301
Drug: Topiramate (TPM)
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate (TPM) at doses of 50, 75, and 100 mg/day
Study: 16647301
Drug: Withdrawal from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal from TPM and substitution with older antiepileptic drugs
Study: 14521743
Drug: Naphtoquine (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naphtoquine (1,000 mg single daily dosage for one day)
Study: 14521743
Drug: Mefloquine (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine (750 mg single dosage)
Study: 14521743
Drug: Artesunate (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artesunate (600 mg total dosage for five days, doubling dosage on the first day)
Study: 6233176
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (CC) + Dexamethasone (DEX) 0.5 mg
Study: 6233176
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (CC) 50 mg on days 5 to 9
Study: 30808567
Drug: RV5 (pentavalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: RV5 (pentavalent rotavirus vaccine)
Study: 22798531
Drug: 15 mL
Normalized name: ethanol 0.15 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mL of mepivacaine 1.5% followed by 15 mL of bupivacaine 0.5% (group A)
Study: 22798531
Drug: 15 mL
Normalized name: ethanol 0.15 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mL of bupivacaine 0.5% followed by 15 mL of mepivacaine 1.5% (group B)
Study: 7608278
Drug: iv dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: iv dexamethasone (2.0‐16.0 mg/day)
Study: 2222952
Drug: felodipine 10
Normalized name: felodipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: felodipine 10 mg extended release once daily
Study: 25690418
Drug: 30 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g/day heat-stabilized rice bran (SRB) for 28 days
Study: 21327796
Drug: Salbutamol 10
Normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol 10 μg/min
Study: 21327796
Drug: Salbutamol 20
Normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol 20 μg/min
Study: 25180798
Drug: Armodafinil 250
Normalized name: armodafinil 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Armodafinil 250 mg
Study: 16684437
Drug: Armodafinil 150
Normalized name: armodafinil 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Armodafinil 150 mg and 250 mg
Study: 15614594
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy (N=65)
Study: 3115786
Drug: DFMO (1.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: DFMO (1.7 g/m sq. t.i.d. added to conventional chemotherapy)
Study: 3115786
Drug: Conventional chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional chemotherapy only (control group of 32 patients)
Study: 29362444
Drug: Active minocycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active minocycline (100 mg b.i.d.) + active aspirin (81 mg b.i.d.) (M + A)